DE60216745D1 - Carbolin Derivate als Hemmstoffe von Phospphodiesterase 5 (PDE5) zur Behandlung kardiovaskulärer Erkrankungen und der erektilen Dysfunktion - Google Patents

Carbolin Derivate als Hemmstoffe von Phospphodiesterase 5 (PDE5) zur Behandlung kardiovaskulärer Erkrankungen und der erektilen Dysfunktion

Info

Publication number: DE60216745D1
Authority: DE; Germany
Prior art keywords: phosphodiesterase; inhibitors; pde5; treatment; cardiovascular diseases
Prior art date: 2001-04-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE60216745T

Other languages

English (en)

Other versions

DE60216745T2 (de

Inventor

Scott Sawyer

W Orme

D Copp

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Lilly Icos LLC

Original Assignee

Lilly Icos LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-25

Filing date

2002-04-02

Publication date

2007-01-25

2002-04-02 Application filed by Lilly Icos LLC filed Critical Lilly Icos LLC

2007-01-25 Application granted granted Critical

2007-01-25 Publication of DE60216745D1 publication Critical patent/DE60216745D1/de

2007-05-16 Publication of DE60216745T2 publication Critical patent/DE60216745T2/de

2022-04-03 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Immunology (AREA)
Hospice & Palliative Care (AREA)
Gynecology & Obstetrics (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

DE60216745T 2001-04-25 2002-04-02 Chemische Verbindungen Expired - Lifetime DE60216745T2 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US28673001P	2001-04-25	2001-04-25
US286730P		2001-04-25
PCT/US2002/010367 WO2002088123A1 (en)	2001-04-25	2002-04-02	Chemical compounds

Publications (2)

Publication Number	Publication Date
DE60216745D1 true DE60216745D1 (de)	2007-01-25
DE60216745T2 DE60216745T2 (de)	2007-05-16

Family

ID=23099912

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE60216745T Expired - Lifetime DE60216745T2 (de)	2001-04-25	2002-04-02	Chemische Verbindungen

Country Status (9)

Country	Link
US (1)	US7115621B2 (de)
EP (1)	EP1383765B1 (de)
JP (1)	JP4216606B2 (de)
AT (1)	ATE348101T1 (de)
CA (1)	CA2441792C (de)
DE (1)	DE60216745T2 (de)
ES (1)	ES2278956T3 (de)
MX (1)	MXPA03009750A (de)
WO (1)	WO2002088123A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI329111B (en)	2002-05-24	2010-08-21	X Ceptor Therapeutics Inc	Azepinoindole and pyridoindole derivatives as pharmaceutical agents
EP1637521B1 (de) *	2003-06-23	2013-06-19	Ono Pharmaceutical Co., Ltd.	Neue tricyclische heterocyclusverbindung
ZA200608176B (en) *	2004-03-15	2008-05-28	Ptc Therapeutics Inc	Carboline derivatives useful in the inhibition of angiogenesis
US8076353B2 (en)	2004-03-15	2011-12-13	Ptc Therapeutics, Inc.	Inhibition of VEGF translation
US8076352B2 (en)	2004-03-15	2011-12-13	Ptc Therapeutics, Inc.	Administration of carboline derivatives useful in the treatment of cancer and other diseases
US7767689B2 (en) *	2004-03-15	2010-08-03	Ptc Therapeutics, Inc.	Carboline derivatives useful in the treatment of cancer
WO2006049986A1 (en) *	2004-10-28	2006-05-11	Dr. Reddy's Laboratories Ltd.	Polymorphic forms of tadalafil
AR051780A1 (es) *	2004-11-29	2007-02-07	Japan Tobacco Inc	Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
US7964726B2 (en)	2004-12-22	2011-06-21	Ono Pharmaceutical Co., Ltd.	Tricyclic compound and use thereof
EP1747779A1 (de)	2005-07-28	2007-01-31	Laboratorios Del Dr. Esteve, S.A.	Tetrahydro-b-carbolinsulfonamid-Derivate als 5-HT6 Liganden
WO2007016361A2 (en) *	2005-07-29	2007-02-08	Concert Pharmaceuticals Inc.	Novel pharmaceutical compounds
WO2007020521A1 (en) *	2005-08-16	2007-02-22	Pharmacia & Upjohn Company Llc	Pyridoyrazinones as pde-5 inhibitors
EP2004644A1 (de) *	2006-03-24	2008-12-24	Glenmark Pharmaceuticals Limited	Verfahren zur herstellung von tadalafil
AU2008302751A1 (en) *	2007-09-20	2009-03-26	D2E, Llc	Fluoro-containing derivatives of hydrogenated pyrido[4,3-b]indoles with neuroprotective and cognition enhancing properties, process for preparing, and use
WO2009089482A1 (en)	2008-01-11	2009-07-16	Albany Molecular Research, Inc.	(1-azinone) -substituted pyridoindoles as mch antagonists
WO2011003012A1 (en) *	2009-07-01	2011-01-06	Albany Molecular Research, Inc.	Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
JP2012532144A (ja)	2009-07-01	2012-12-13	アルバニーモレキュラーリサーチ，インコーポレイテッド	アジノン置換アゼピノ［ｂ］インドールおよびピリド−ピロロ−アゼピンｍｃｈ−１拮抗薬、ならびにその作製方法および使用
WO2011003007A1 (en)	2009-07-01	2011-01-06	Albany Molecular Research, Inc.	Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
US9073925B2 (en) *	2009-07-01	2015-07-07	Albany Molecular Research, Inc.	Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
US8993765B2 (en)	2010-12-21	2015-03-31	Albany Molecular Research, Inc.	Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
WO2012088038A2 (en)	2010-12-21	2012-06-28	Albany Molecular Research, Inc.	Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
TW201309698A (zh)	2011-03-18	2013-03-01	Ono Pharmaceutical Co	四氫咔啉衍生物
CN102391323B (zh) *	2011-10-18	2013-09-25	首都医科大学	四氢-β-咔啉衍生物、其制备方法及其用途
TW201710258A (zh)	2015-06-23	2017-03-16	碩騰服務公司	咔啉抗寄生蟲藥

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES273769A1 (es) *	1961-01-18	1962-06-01	Geigy Ag J R	Procedimiento para la preparaciën de nuevos derivados de amidas de acido beta-carbolin-carboxilico
JPS5543475B2 (de) *	1972-09-14	1980-11-06
US4336260A (en) *	1977-12-08	1982-06-22	The Dow Chemical Company	Method and compositions using 1-aryl-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid for treating depression
JPS5936676A (ja) *	1982-08-20	1984-02-28	Tanabe Seiyaku Co Ltd	β−カルボリン誘導体の新規製法
FR2663935A1 (fr) *	1990-06-27	1992-01-03	Adir	Nouveaux 1,2,3,4,5,6-hexahydroazepino [4,5-b] indoles et 1,2,3,4-tetrahydrobethacarbolines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
GB9401090D0 (en) *	1994-01-21	1994-03-16	Glaxo Lab Sa	Chemical compounds
GB9514473D0 (en)	1995-07-14	1995-09-13	Glaxo Lab Sa	Chemical compounds
ES2169857T3 (es) *	1996-04-04	2002-07-16	Hoffmann La Roche	Uso de derivados de tetrahidro-beta-carbolinas como agentes antimetastaticos.
SK154498A3 (en) *	1996-05-10	2000-01-18	Icos Corp	Carboline derivatives, process for the preparation thereof, pharmaceutical compositions containing same and use of mentioned derivatives as drugs
WO1997043267A1 (en)	1996-05-11	1997-11-20	Kings College London	Pyrazines
US6043252A (en) *	1997-05-05	2000-03-28	Icos Corporation	Carboline derivatives
CA2339630C (en)	1998-09-16	2006-05-23	Icos Corporation	Carboline derivatives as cgmp phosphodiesterase inhibitors
EA004872B1 (ru)	1999-08-03	2004-08-26	ЛИЛЛИ АЙКОС эЛ-эЛ-Си	β-КАРБОЛИНОВЫЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
UA74826C2 (en) *	2000-05-17	2006-02-15	Ortho Mcneil Pharm Inc	?-carboline derivatives as phosphodiesterase inhibitors
AU2001268064A1 (en) *	2000-06-07	2001-12-17	Lilly Icos Llc	Derivatives of 2,3,6,7,12,12a-hexahydropyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
US20030153575A1 (en)	2000-06-08	2003-08-14	Orme Mark W.	Tetracyclic diketopiperazine compounds as pdev inhibitors
MXPA03002911A (es)	2000-10-03	2003-09-10	Lilly Icos Llc	Compuestos quimicos.
DE60122559T2 (de)	2000-11-06	2006-12-07	Lilly Icos Llc, Wilmington	Indolderivate als pde5-inhibitoren

2002
- 2002-04-02 MX MXPA03009750A patent/MXPA03009750A/es active IP Right Grant
- 2002-04-02 ES ES02766739T patent/ES2278956T3/es not_active Expired - Lifetime
- 2002-04-02 JP JP2002585422A patent/JP4216606B2/ja not_active Expired - Fee Related
- 2002-04-02 US US10/471,476 patent/US7115621B2/en not_active Expired - Fee Related
- 2002-04-02 AT AT02766739T patent/ATE348101T1/de not_active IP Right Cessation
- 2002-04-02 DE DE60216745T patent/DE60216745T2/de not_active Expired - Lifetime
- 2002-04-02 WO PCT/US2002/010367 patent/WO2002088123A1/en active IP Right Grant
- 2002-04-02 EP EP02766739A patent/EP1383765B1/de not_active Expired - Lifetime
- 2002-04-02 CA CA2441792A patent/CA2441792C/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ES2278956T3 (es)	2007-08-16
CA2441792C (en)	2010-08-03
JP4216606B2 (ja)	2009-01-28
EP1383765B1 (de)	2006-12-13
WO2002088123A1 (en)	2002-11-07
DE60216745T2 (de)	2007-05-16
US7115621B2 (en)	2006-10-03
MXPA03009750A (es)	2004-06-30
CA2441792A1 (en)	2002-11-07
US20040147542A1 (en)	2004-07-29
EP1383765A1 (de)	2004-01-28
JP2004532852A (ja)	2004-10-28
ATE348101T1 (de)	2007-01-15

Publication	Publication Date	Title
DE60216745D1 (de)	2007-01-25	Carbolin Derivate als Hemmstoffe von Phospphodiesterase 5 (PDE5) zur Behandlung kardiovaskulärer Erkrankungen und der erektilen Dysfunktion
EA200200208A1 (ru)	2002-08-29	Синергитическая композиция
ATE302775T1 (de)	2005-09-15	Carbolinderivate
ATE371656T1 (de)	2007-09-15	Heteroaryl-pyrimidinderivate als jak-inhibitoren
ES2170252T3 (es)	2002-08-01	Tetrahidroimidazopiridoindoldionas como inhibidores de cgmp especifico pde.
RS99203A (en)	2006-12-15	Pyrrolopyrimidines as protein kinase inhibitors
AU5584901A (en)	2001-10-30	Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
CY1107747T1 (el)	2013-04-18	Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
EA200700099A1 (ru)	2007-08-31	Производные пиридина
ATE346067T1 (de)	2006-12-15	Carbolinderivate
ATE307810T1 (de)	2005-11-15	Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
ATE332903T1 (de)	2006-08-15	Kondensierte pyridoindolderivate
MXPA05012247A (es)	2006-02-10	Derivados de bencimidazol nuevos.
AP2003002929A0 (en)	2003-12-31	Pyrrolopyrimidines as protein kinase inhibitors
DE60112306D1 (de)	2005-09-01	Kondensierte pyrazindionderivate als pde5 inhibitore
ATE357438T1 (de)	2007-04-15	1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
ECSP055809A (es)	2005-08-11	Inhibidores 4-oxo-1-(3-fenil sustituido)-1,4-dihidro-1,8-naftiridina-3-carboxamida de la fosfodiesterasa-4
ATE389655T1 (de)	2008-04-15	Pyrimidinderivate
ATE302776T1 (de)	2005-09-15	Kondensierte pyridoindolderivate
ATE333457T1 (de)	2006-08-15	Zyklische gmp-spezifische phosphodiesteraseinhibitoren
DE60226970D1 (de)	2008-07-17	Pyrazinoä1',2':1,6ü-pyridoä3,4-bü indole-1,4-dionderivate
ATE337320T1 (de)	2006-09-15	Indolderivate als pde5-inhibitoren
MXPA03004023A (es)	2004-02-12	Compuestos quimicos.
ATE297926T1 (de)	2005-07-15	Hexahydropyrazino(1'2':1,6)-pyrido(3,4-b)indole 1,4-dion-derivate zur behandlung von cardiovaskulären erkrankungen und erektionsstörungen
ATE335742T1 (de)	2006-09-15	Carbolinderivate als pdev inhibitoren

Legal Events

Date	Code	Title	Description
2008-01-03	8364	No opposition during term of opposition
2012-02-01	R082	Change of representative	Ref document number: 1383765 Country of ref document: EP Representative=s name: BOEHMERT & BOEHMERT, 28209 BREMEN, DE

Date

Code

Title

Description

2008-01-03

8364

No opposition during term of opposition

2012-02-01

R082

Change of representative

Ref document number: 1383765

Country of ref document: EP

Representative=s name: BOEHMERT & BOEHMERT, 28209 BREMEN, DE